Supreme Court Hears ‘Pay to Delay’ Case

The Supreme Court began hearing arguments in the so-called “pay to delay” policy by some pharmaceutical giants which cut deals with generic drug companies to keep their cheaper versions of brand-name medicines off the market. Critics say its anti-competitive and ends up costing consumers more money. Bertha Coombs has the story for NBR.

This entry was posted in Markets. Bookmark the permalink.

Leave a Reply